KRChoksey's research report on Dr. Reddy's Laboratories
Dr Reddy’s Labs reported Q1FY18 revenue of INR 33,332 mn which grew 1.98% Y-o-Y but degrew 7.13% Q-o-Q due to price erosion and channel consolidation in the US along with destocking of inventories due to GST in India. However, the company has witnessed a growing trend in the emerging market and Europe due to volume uptake and new product launches..
Outlook
At CMP of INR 2,478 the stock is trading at EPS of INR 77.9 in FY17 and we project EPS of INR 78.8 in FY19E . We recommend “HOLD” rating on the stock and value the stock at 32x, its FY19E EPS and arrive at a target price of INR 2,523 indicating 1.8% upside from CMP.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.